Results 161 to 170 of about 1,208 (179)

Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics [PDF]

Translational Oncology
Background: In the context of hormone receptor positive, HER2 negative Metastatic breast cancer (MBC), CDK 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the standard first-line treatment, improving Progression-Free Survival (PFS) and
Alessandro Marco Minisini, Fabiola Giudici, Arianna Dri   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer

Cancer Research
Abstract Colorectal cancer is frequently diagnosed in advanced stages, highlighting the need for developing approaches for early detection. Liquid biopsy using cell-free DNA (cfDNA) fragmentomics is a promising approach, but the clinical application is hindered by complexity and cost.
Yuepeng Cao, Nannan Wang, Xuxiaochen Wu, Wanxiangfu Tang, Hua Bao, Chengshuai Si, Peng Shao, Dongzheng Li, Xin Zhou, Dongqin Zhu, Shanshan Yang, Fufeng Wang, Guoqing Su, Ke Wang, Qifan Wang, Yao Zhang, Qiangcheng Wang, Dongsheng Yu, Qian Jiang, Jun Bao, Liu Yang   +20 more
openaire   +2 more sources

cfDNA fragmentomics for preeclampsia prediction

To investigate whether cfDNA fragmentomic features have the potential to predict early-onset or late-onset PE, we performed WGS of plasma cfDNA (>10X final read depth) from pregnant women with PE (n=109 for early-onset PE, n=333 for late-onset PE) and sampling-gestation-matched healthy controls (n=476).
openaire   +1 more source

Integration of cfDNA fragmentomics for early biliary tract cancer detection.

Journal of Clinical Oncology
4131 Background: Biliary Tract Cancer (BTC) is a highly aggressive malignancy with poor survival outcomes, primarily due to the lack of effective early detection methods and late-stage diagnoses.
Jiwen Wang, Xiaojian Ni, Yuxuan Zheng, Qingxin Xie, Hua Bao, Kun Fan, Dongqin Zhu, Hairong Bao, Ruowei Yang, Chunyan Wang, Bohao Zheng, Shuang Chang, Xiuxiu Xu, Haimeng Tang, Xiaoling Ni, Tao Suo, Xue Wu, Sheng Shen, Han Liu, Houbao Liu   +19 more
openaire   +1 more source

Cell-free DNA fragmentomics and methylomics for thymic epithelial tumors.

Journal of Clinical Oncology
8118 Background: Development of circulating cell-free (cf) DNA assays for cancer detection and monitoring is an area of active research. Limited data are available on the utility of cfDNA for thymic epithelial tumors (TETs).
Michael Daniels, Elizabeth R. Francis, Ling Su, Xiaolin Wu, Elsa Bahiru, Shannon Swift, Christine Feierabend, Susan Sansone, Laercio Lopes DaSilva, Eva Szabo, Chen Zhao, Meredith Jo McAdams, Arun Rajan   +12 more
openaire   +1 more source

Prospective Evaluation of cfDNA Fragmentomes for Lung Cancer Detection

C99. ADVANCES IN BIOMARKERS ACROSS THE LUNG CANCER CONTINUUM, 2023
P.J. Mazzone, K.-K. Wong, J.J. Tsay, A. Vachani, A. Ryan, J. Carey, D. Jakubowski, K. Lumbard, J. Catallini, T. Maddala, P.B. Bach, R. Scharpf, N. Dracopoli, V. Velculescu   +13 more
openaire   +1 more source

Plasma cell-free DNA fragmentomic bioinformatics development

Cell-free DNA (cfDNA) liquid biopsy technology is widely applied in non-invasive prenatal testing (NIPT). Traditional NIPT approaches that only utilize single genetic markers frequently yield inaccurate and unstable testing results, particularly in clinical samples with lower fetal fetal fraction, which limits diagnostic reliability.
openaire   +1 more source

Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas

Seminars in Hematology, 2023
Leo Meriranta, Sirpa Leppä, Esa Pitkänen   +2 more
exaly  

METHODS AND COMPOSITIONS FOR DETECTING CANCER USING FRAGMENTOMICS

2022
KRUGLYAK KRISTINA, MARASS FRANCESCO, TSUI WAI YI   +2 more
openaire   +1 more source

Fragmentomics of proteins and natural oligopeptides

Biophysics, 2009
A A Zamyatnin
exaly